Valvular & structural heart diseaseCohort study
Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices
- Retrospective cohort study
- multicentre
- propensity-score matched
Authors' conclusion
T-TEER is safe and effective in selected patients with transvalvular CIED leads. Effective TR reduction remains prognostically relevant, even in this high-risk real-world population.
Study context
- Population
- Patients with severe tricuspid regurgitation (TR) undergoing T-TEER at 26 centres (2016–2024)
- Participants
- 3,025 patients · 385 matched pairs
- Exposure
- T-TEER in patients with vs without transvalvular CIED leads
- CIEDn = 851
- Outcome
- Composite of:
- All-cause mortality
- HF hospitalization
- Follow-up
- 2 years
Main finding
2-year HF hospitalization-free survival
Hazard ratio
1.31
95% CI 0.99–1.74
P = 0.063
By group
CIED vs No CIED
HR 1.31 (95% CI 0.99–1.74); P = 0.063
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Residual TR >2+ | 0.98 (0.70–1.38) | P = 0.915 | |
| 0.512Odds ratio (log scale) |
Residual TR (CIED) · discharge and follow-up (median 269 days; Q1-Q3: 63-423 days)
- TR ≤1+ at discharge
- 39.9%
- TR ≤2+ at discharge
- 79.8%
- TR ≤1+ at follow-up
- 29.3%
- TR ≤2+ at follow-up
- 69.1%
Survival by residual TR ≤2+
- Residual TR ≤2+ conferred significantly better survival irrespective of CIED presence
- P < 0.001
Safety
CIED function and lead revision
- CIED function remained stable; no lead revision required
Original publication
Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices. JACC Cardiovasc Interv. Published 25 October 2025. doi:10.1016/j.jcin.2025.09.033
Summarised from the published abstract; every number is checked against it